Table 1 Melphalan pharmacokinetic parameters and its association with transplant toxicity and short term outcomes.
From: Still learning the right way to administer melphalan in autologous transplantation
Ref. | Melphalan dose (mg/m2) | Creatinine clearance (mL/min) | AUC (mg/L h) | Melphalan clearance (L/min) | Volume of distribution-central (V1d) (L) | t1/2 β (min) | Mucositis | Infection | Engraftment (platelet) | Hospital Stay |
|---|---|---|---|---|---|---|---|---|---|---|
Association with melphalan AUC | ||||||||||
Moreau et al. [6] | 220 140 Day-2 | NA | 6.27–16.78 4–10.67 (3-fold) | 0.16–0.56/m2 (3.5-fold) | 6.0–19.9 /m2 (3-fold) | 23–60 (2.5-fold) | + | NA | + | NA |
Kuhne et al. [5] | 130–200 | 11.9–179.8 | Value NA (1.7–4.3-fold) | 0.18–1.0 3 (6-fold) | 7.0–77.4 (11-fold) | NA | + | NA | NA | NA |
Nath et al. [4] | 200 Day-2 | 29–234 | 4.9–24.2 (5-fold) | 0.46 (33.6 %CV) | 13.1 (59.5 %CV) | NA | + | NA | NA | + |
Nampoothiri et al. [3] | 140–200 Day-1 (T-24 h) | 23.9–144 | 10.0–110.2 (11-fold) | 0.04–1.2 (30-fold) | 10–94 (9-fold) | 10–414 (40-fold) | + | + | − | + |
